Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Davidson

Endocrinology, Diabetes & Metabolism Dover, NH Doctor of Osteopathy

NPI 1225109168 CMS profile 55104

10 Members Way, Suite 400, Dover, NH 03820

Open in the dashboard

General payments

$204,170

400 records reported · program years 2019–2024

Research payments

$648

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Davidson of Dover, NH is reported in the CMS Open Payments database as having received $204,170 across 400 general payments and $648 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $648 1
2022 General $918 1
2021 General $33,039 50
2020 General $65,599 137
2019 General $104,614 212

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Davidson
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michael Davidson were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michael Davidson Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $104,614 $494 $123–$2,253 $163
2020 $65,599 $335 $85–$1,841 $114
2021 $33,039 $398 $88–$1,981 $132
2022 $918 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lilly USA, LLC $184,871 361 payments
  2. Dexcom, Inc. $14,318 18 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,316 3 payments
  4. Medtronic, Inc. $1,250 1 payment
  5. AstraZeneca Pharmaceuticals LP $1,184 7 payments
  6. Tandem Diabetes Care, Inc. $1,117 5 payments
  7. Mannkind Corporation $59 1 payment
  8. Medtronic MiniMed, Inc. $42 3 payments
  9. Novo Nordisk Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $151,164 166 payments
  2. Travel and Lodging $35,994 100 payments
  3. Consulting Fee $11,785 8 payments
  4. Food and Beverage $4,235 122 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $918 1 payment
  6. Gift $59 1 payment
  7. Education $14 2 payments
Products named General payments · program years 2019–2024
  1. TRULICITY $95,574 159 payments
  2. BAQSIMI $41,496 68 payments
  3. Dexcom G6 CGM System $9,863 13 payments
  4. DEXCOM G6 TRANSMITTER Endocrinology $3,519 3 payments
  5. JARDIANCE Diabetes $2,478 8 payments
  6. JARDIANCE Diabetes $1,316 3 payments
  7. t-slim insulin pump $1,117 5 payments
  8. FARXIGA $1,032 3 payments
  9. Dexcom G6 Transmitter Endocrinology $918 1 payment
  10. AFREZZA $59 1 payment
  11. Other $85 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Dexcom, Inc. $648 1 payment

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record